Veru Inc. (VERU) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate mixed signals. While the company shows progress in drug development and partnership discussions, financial health raises concerns due to insufficient cash for long-term operations and a significant net loss. The potential for new partnerships and an improved formulation could be positive, but financial constraints and the need for substantial capital for Phase III trials temper expectations. The market is likely to react cautiously, resulting in a neutral sentiment.
Key Financial Performance
Research and Development Costs (Q3 2025) $3 million, decreased from $4.8 million in the prior quarter (a 37.5% decrease). The decrease is primarily due to the wind down of the company's Phase IIb QUALITY clinical study for enobosarm, which was completed during the quarter.
Selling, General and Administrative Expenses (Q3 2025) $5 million, decreased from $5.8 million in the prior quarter (a 13.8% decrease). The decrease is primarily due to a reduction in share-based compensation.
Net Loss from Continuing Operations (Q3 2025) $7.3 million or $0.50 per diluted common share, compared to $10.3 million or $0.71 per diluted common share in the prior year's quarter (a 29.1% improvement).
Net Loss from Discontinued Operations (Q3 2025) $9,700 or $0.00 per diluted common share, compared to $629,000 or $0.04 per diluted common share in the prior quarter (a significant improvement).
Research and Development Costs (9 months ended June 30, 2025) $12.7 million, increased from $9.5 million in the prior period (a 33.7% increase). The increase is due to $4.5 million incurred for the Phase IIb QUALITY clinical study for enobosarm, partially offset by a decrease in expenditures for other terminated drug development programs.
Selling, General and Administrative Expenses (9 months ended June 30, 2025) $15.4 million, decreased from $18.4 million in the prior period (a 16.3% decrease). The decrease is primarily due to a reduction in share-based compensation.
Net Loss from Continuing Operations (9 months ended June 30, 2025) $17 million or $1.16 per diluted common share, compared to $26.7 million or $2.04 per diluted common share in the prior period (a 36.3% improvement).
Net Loss from Discontinued Operations (9 months ended June 30, 2025) $7.2 million or $0.49 per diluted common share, compared to $2.6 million or $0.20 per diluted common share in the prior period (a 176.9% increase). The increase is due to the $4.3 million loss on the sale of the FC2 Female Condom business and a $3.2 million increase in the loss from the change in fair value of derivative liabilities, partially offset by a $3.9 million decrease in selling, general and administrative expenses.
Cash, Cash Equivalents, and Restricted Cash (as of June 30, 2025) $15 million, decreased from $24.9 million as of September 30, 2024 (a 39.8% decrease).
Net Working Capital (as of June 30, 2025) $9.5 million, decreased from $23.4 million as of September 30, 2024 (a 59.4% decrease).
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Enobosarm: A next-generation drug that enhances GLP-1 receptor agonist weight loss by targeting fat loss while preserving lean mass. Demonstrated significant results in Phase IIb QUALITY study, including 100% preservation of lean mass and a 42% greater fat loss with the 6-mg dose compared to placebo. Positive safety profile and efficacy in preventing weight regain after semaglutide discontinuation.
Sabizabulin: An oral microtubule disruptor being developed to reduce vascular plaque inflammation and slow progression of atherosclerotic cardiovascular disease. No new updates provided in this call.
Target Market Expansion: Focus on older patients (60+ years) with obesity, particularly those with sarcopenic obesity. Potential expansion into younger populations with obesity, diabetes, and frailty.
Financial Adjustments: Research and development costs decreased to $3 million due to the wind-down of the Phase IIb QUALITY study. Selling, general, and administrative expenses also decreased to $5 million. However, the company reported a net loss of $7.3 million for the quarter.
Cash Flow and Capital: Cash balance reduced to $15 million as of June 30, 2025. The company requires additional capital to fund operations beyond the next calendar year.
Strategic Shift: Sale of the FC2 Female Condom business to focus exclusively on drug development. Proceeds from the sale were used to support ongoing operations and drug development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Clarity and Approval: The company is awaiting regulatory clarity from the FDA for its Phase III clinical program for enobosarm. Delays or unfavorable outcomes in regulatory approval could impact the timeline and success of the drug's commercialization.
Financial Sustainability: The company reported a net loss of $17 million for the 9 months ended June 30, 2025, and has negative cash flow from operations. It will require additional capital to fund operations beyond the next calendar year, posing a risk to its financial stability.
Market Competition: The company faces competition in the obesity and weight management market, particularly from existing GLP-1 receptor agonists. This could impact the market adoption of enobosarm.
Dependence on Clinical Trial Success: The success of enobosarm and its combination with semaglutide is heavily dependent on the outcomes of clinical trials. Any failure or delay in achieving positive results could adversely affect the company's strategic objectives.
Supply Chain and Manufacturing Risks: The company is developing a novel modified release oral formulation for enobosarm, which involves a unique manufacturing process. Any disruptions or challenges in manufacturing could delay the Phase III clinical study and commercialization.
Strategic Focus Shift: The sale of the FC2 Female Condom business represents a strategic shift to focus exclusively on drug development. This transition may pose risks if the new focus does not yield expected results.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Phase III Clinical Program for Enobosarm: The company expects regulatory clarity for the GLP-1 receptor agonist and enobosarm combination Phase III program following an end of Phase II FDA meeting scheduled this quarter. The proposed indication is for enobosarm as an adjunct to GLP-1 receptor agonists to preserve lean mass and improve physical function in older adults with obesity.
Target Population for Enobosarm: The Phase III clinical program will focus on older adults over 60 years of age who are at higher risk for muscle weakness and falls due to age-related muscle loss. This population represents a significant market, with 47.4 million patients over 60 enrolled in Medicare Part D, of which 41.5% could benefit from obesity treatment.
Potential Expansion of Enobosarm Use: Success in the older population could lead to expansion into younger patients with obesity, as well as diabetic and frailty populations.
Novel Modified Release Oral Formulation of Enobosarm: The company has developed a novel modified release oral formulation of enobosarm, which demonstrated a distinct target product release profile in a pharmacokinetic clinical study. This formulation is planned for use in the Phase III clinical study and commercialization. Patents for this formulation are expected to provide protection through 2046.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On the modified release formulation of enobosarm, does this new formulation allow for fixed dose combinations, particularly with oral GLP-1s?
A:Yes, the new formulation allows for fixed dose combinations with oral GLP-1s. This could add additional patent life and be beneficial for addressing muscle loss associated with GLP-1 receptor agonists.
Q:Are there any updates on partnering ex U.S. and discussions about the novel formulation?
A:Yes, the company is actively discussing partnerships with two main groups: major players like Novo Nordisk and Lilly, and other companies developing GLP-1s. They aim to secure non-dilutive funding for future studies.
Q:What are the expectations for the end of Phase II meeting with the FDA and the proposed Phase III design?
A:The company expects the FDA to confirm the need for a physical function measurement as a primary endpoint. They anticipate potential pushback on expanding the patient population beyond older adults. Feedback from the FDA is expected by late August or September.
Q:How will the company communicate the outcome of the FDA meeting?
A:The company will wait for official written feedback from the FDA and expects to provide clarity by late August or September.
Q:Will the modified release formulation have a better side effect profile than the current formulation?
A:Yes, the modified release formulation is expected to have a better safety profile due to reduced Cmax and delayed Tmax, while maintaining similar efficacy.
Q:What does the company need to show the FDA for the new formulation to be included in Phase III?
A:The company needs to conduct a formal relative bioavailability study to demonstrate that the area under the plasma concentration time curve (AUC) is similar between the immediate release and modified release formulations.
Q:Can you discuss the proposed Phase III trial design and its endpoints?
A:The Phase III trial will replicate the successful Phase IIb study for short-term endpoints like lean mass and physical function. It will also include long-term assessments for bone mineral density and incremental weight loss. The design includes dechallenge and rescue portions to assess efficacy and safety comprehensively.
Q:When can we expect full data from the induction and maintenance trials?
A:The company is targeting ObesityWeek in November for presenting additional data.
Q:What is the confidence level in obtaining patents for the new formulation?
A:The company is confident in obtaining patents due to the novel 3D printing technology used, which makes it difficult for generics to replicate. Preliminary feedback from the International Patent Office indicates the claims are novel.
Q:Will there be an open-label extension for the Phase III trial?
A:Currently, there is no plan for an open-label extension as the company believes the safety database will meet FDA requirements. However, this could change based on regulatory or commercial needs.
Q:Will the Phase III trial target specific subpopulations like those with sarcopenia or osteoporosis?
A:The trial will focus on older patients over 60 who are obese but not diabetic, as they are at higher risk for muscle and bone loss. The design aims to capture a broad range of patients without overly restricting the population.
Q:Will the trial monitor falls, fractures, and hospitalizations?
A:Yes, falls and fractures will be monitored as adverse events, and they may be considered adverse events of special interest in the longer study.
Q:How much capital is estimated to be needed for the Phase III trial?
A:The company estimates needing approximately $40 million over 18 months, but this will be finalized after receiving FDA feedback.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact capital needs for the Phase III trial, stating they would wait for FDA feedback before finalizing the estimate.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FC Female
Female Condom
III program
IIb QUALITY
Inc Research
LLC
Maintenance Extension
Phase III
Phase IIb
Phase QUALITY
Purvis
QUALITY study
QUALITY trial
Research Division
Veru Inc
climb power
decline stair
discontinuation
enobosarm milligram
formulation
milligram group
milligram value
monotherapy group
placebo monotherapy
placebo semaglutide
plasma concentration
pound
sale FC
semaglutide group
share stock
stock split
study enobosarm
value enobosarm
VERU Transcript
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Unknown5-13
The earnings call summary reflects a negative sentiment due to declining revenue, decreased gross margin, and reduced net income, all of which are concerning for investors. The increased R&D expenses, while potentially beneficial in the long term, contribute to the current financial strain. The absence of strategic initiatives or positive guidance further exacerbates the negative outlook. Additionally, the lack of clarity in management's responses during the Q&A session adds to investor uncertainty, likely leading to a negative stock price movement in the short term.
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Unknown2-11
The earnings call presents a mixed picture. While there are positive developments in clinical trials and financial improvements, significant risks and challenges remain. The regulatory hurdles for enobosarm, bone density concerns, and intense market competition could weigh on investor sentiment. The Q&A session did not reveal any new risks, but the lack of profitability and the need for clear market advantages are concerns. The financial position shows improved cash reserves, but sustainability is uncertain. These factors balance each other out, leading to a neutral sentiment rating.
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Positive12-17
The earnings call highlights several positive aspects: a significant reduction in net loss, gains from asset sales, and a promising new formulation of enobosarm with extended patent protection. While there are concerns about increased cash use and unclear management responses, the overall strategic direction, market potential, and regulatory flexibility provide a positive outlook, likely resulting in a 2% to 8% stock price increase.
Veru Inc. (VERU) Q3 2025 Earnings Call Transcript
Unknown8-12
The earnings call summary and Q&A indicate mixed signals. While the company shows progress in drug development and partnership discussions, financial health raises concerns due to insufficient cash for long-term operations and a significant net loss. The potential for new partnerships and an improved formulation could be positive, but financial constraints and the need for substantial capital for Phase III trials temper expectations. The market is likely to react cautiously, resulting in a neutral sentiment.
VERU Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
